Regeneron Pharmaceuticals (REGN) Receivables - Net (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Receivables - Net of $6.6 billion for Q2 2026, up 17.03% year-over-year from $5.6 billion in Q2 2025, and up 14.56% quarter-over-quarter from $5.7 billion in Q1 2026.
Regeneron Pharmaceuticals (REGN) Receivables - Net (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Receivables - Net history runs 18 years deep, the most recent figure standing at $6.6 billion for Q2 2026.
- In Q2 2026, Receivables - Net rose 17.03% year-over-year to $6.6 billion; the TTM figure through Jun 2026 stood at $6.6 billion (up 17.03% YoY), while the FY2025 annual figure was $5.7 billion, down 7.58% from the prior year.
- Receivables - Net for Q2 2026 stood at $6.6 billion, up from $5.7 billion in the prior quarter.
- The five-year high for Receivables - Net was $6.6 billion in Q2 2026, with the low at $4.8 billion in Q1 2022.
- The 5-year median for Receivables - Net is $5.6 billion (2023), against an average of $5.6 billion.
- The sharpest annual moves came in 2022 and 2026: Receivables - Net slipped 26.25% in 2022, then climbed 17.03% in 2026.
- Regeneron Pharmaceuticals' Receivables - Net stood at $5.3 billion in 2022, then gained by 6.35% to $5.7 billion in 2023, then grew by 9.61% to $6.2 billion in 2024, then retreated by 7.58% to $5.7 billion in 2025, then increased by 14.36% to $6.6 billion in 2026.
- Business Quant data shows REGN's Receivables - Net at $6.6 billion in Q2 2026, $5.7 billion in Q1 2026, and $5.7 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.57 Bn |
| Jun 30, 2026 | 6.57 Bn |
| Mar 31, 2026 | 5.73 Bn |
| Mar 31, 2026 | 5.73 Bn |
| Dec 31, 2025 | 5.74 Bn |
| Dec 31, 2025 | 5.74 Bn |
| Sep 30, 2025 | 5.69 Bn |
| Sep 30, 2025 | 5.69 Bn |
| Jun 30, 2025 | 5.61 Bn |
| Jun 30, 2025 | 5.61 Bn |
| Mar 31, 2025 | 5.56 Bn |
| Mar 31, 2025 | 5.56 Bn |
| Dec 31, 2024 | 6.21 Bn |
| Dec 31, 2024 | 6.21 Bn |
| Sep 30, 2024 | 6.11 Bn |
| Sep 30, 2024 | 6.11 Bn |
| Jun 30, 2024 | 5.72 Bn |
| Jun 30, 2024 | 5.72 Bn |
| Mar 31, 2024 | 5.22 Bn |
| Mar 31, 2024 | 5.22 Bn |